Erasca, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company's lead candidates include ERAS-007, an oral inhibitor of ERK1/2 for the treatment of non-small cell lung cancer, colorectal cancer, and acute myeloid leukemia; and ERAS-601, an oral SHP2 inhibitor for patients with advanced or metastatic solid tumors. It is also developing ERAS-801, a central nervous system-penetrant EGFR inhibitor for the treatment of patients with recurrent glioblastoma multiforme. The company was incorporated in 2018 and is headquartered in San Diego, California.

CEO

ISIN

US29479A1088

Listings

0 Comments

Share your thoughts

FAQ

What is Erasca stock price today?▼

The current price of ERAS.BOATS is $16.66 USD — it has increased by +4.13% in the past 24 hours. Watch Erasca stock price performance more closely on the chart.

What is Erasca stock ticker?▼

Depending on the exchange, the stock ticker may vary. For instance, on exchange Erasca stocks are traded under the ticker ERAS.BOATS.

What is Erasca market cap?▼

Today Erasca has the market capitalization of 4.73B

When is the next Erasca earnings date?▼

Erasca is going to release the next earnings report on May 07, 2026.

What were Erasca earnings last quarter?▼

ERAS.BOATS earnings for the last quarter are -0.1 USD per share, whereas the estimation was -0.11 USD resulting in a +6.54% surprise. The estimated earnings for the next quarter are N/A USD per share.

What is Erasca revenue for the last year?▼

Erasca revenue for the last year amounts to 0 USD.

What is Erasca net income for the last year?▼

ERAS.BOATS net income for the last year is -323.3M USD.

When did Erasca complete a stock split?▼

Erasca has not had any recent stock splits.